MAP1LC3A and Alzheimer disease: EEA1, LAMP-1, LAMP-2 and LC3 have the potential to be used to monitor the disease progression because lysosomal network changes in AD are progressive with slow changes, leading to a buildup of incompletely digested substrates within neuronal processes.